51. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1
- Author
-
Pham Van Cuong, Nguyen Tien Dat, Jeong-Hyung Lee, Cheol Hwangbo, Suhyun Lee, Chau Van Minh, Nguyen Hai Dang, and Phuong Thao Tran
- Subjects
musculoskeletal diseases ,MAPK/ERK pathway ,Male ,Reishi ,p38 mitogen-activated protein kinases ,Pharmaceutical Science ,Osteoclasts ,Bone resorption ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Western blot ,Osteoclast ,Osteogenesis ,Drug Discovery ,medicine ,Animals ,Viability assay ,Bone Resorption ,Phosphorylation ,Extracellular Signal-Regulated MAP Kinases ,Cells, Cultured ,030304 developmental biology ,Pharmacology ,0303 health sciences ,Mice, Inbred ICR ,biology ,medicine.diagnostic_test ,Dose-Response Relationship, Drug ,NFATC Transcription Factors ,Chemistry ,RANK Ligand ,Cell Differentiation ,Cell biology ,Hydroquinones ,medicine.anatomical_structure ,RAW 264.7 Cells ,Complementary and alternative medicine ,Gene Expression Regulation ,RANKL ,030220 oncology & carcinogenesis ,biology.protein ,Molecular Medicine ,Signal transduction - Abstract
Background Many bone-related diseases such as osteoporosis and rheumatoid arthritis are commonly associated with excessive activity of the osteoclast. Ganomycin I (GMI), a meroterpenoid isolated from Vietnamese mushroom Ganoderma lucidum, possesses a variety of beneficial effects on human health. However, its impact and underlying mechanism on osteoclastogenesis remain unclear. In the present study, we investigated the effect of GMI on RANKL-induced osteoclast formation in mouse BMMs and RAW264.7 cells. Methods BMMs or RAW264.7 cells were treated with GMI followed by an evaluation of cell viability, RANKL-induced osteoclast differentiation, actin-ring formation, and resorption pits activity. Effects of GMI on RANKL-induced phosphorylation of MAPKs as well as the expression levels of NFATc1 and c-Fos were evaluated by Western blot analysis. Expression levels of osteoclast marker genes were evaluated by Western blot analysis and reverse transcription-qPCR. Results GMI significantly inhibited RANKL-induced osteoclast differentiation by decreasing the number of osteoclasts, osteoclast actin-ring formation, and bone resorption in a dose-dependent manner without affecting cell viability. At molecular level, GMI inhibited the RANKL-induced phosphorylation of ERK, JNK, and p38 MAPKs, as well as the expression levels of c-Fos and NFATc1, which are known to be crucial transcription factors for osteoclast formation. In addition, GMI decreased expression levels of osteoclastogenesis specific marker genes including c-Src, CtsK, TRAP, MMP-9, OSCAR, and DC-STAMP in RANKL-stimulated BMMs. Conclusion Our findings suggest that GMI can attenuate osteoclast formation by suppressing RANKL-mediated MAPKs and NFATc1 signaling pathways and the anti-osteoclastogenic activity of GMI may extend our understanding of molecular mechanisms underlying biological activities and pharmacological use of G. lucidum as a traditional anti-osteoporotic medicine.
- Published
- 2018